You Might Also Like
Also By This Author
- UCB. News release: UCB and Amgen announce positive topline results from phase 3 study evaluating romosozumab in men with osteoporosis. 2016 Mar 21.
- Amgen Inc. News release: Amgen and UCB present positive data at ENDO 2016 comparing romosozumab with teriparatide. 2016 Apr 1.
- Janssen Pharmaceutical Companies. News release: Janssen announces discontinuation of fulranumab phase 3 development program in osteoarthritis pain. 2016 Mar 31.